Pipeline updates are highly awaited events in the
pharma/biotech sector as they play an important role in deciding
whether or not to invest in a particular company. These updates
provide information on experimental drugs and at times provide an
insight into the commercial potential of the candidate once it is
successfully developed and commercialized.
FOREST LABS A (FRX): Free Stock Analysis
HEAT BIOLOGICS (HTBX): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.
Earlier this week,
Heat Biologics, Inc.
) announced that a phase I/II study on its oncology candidate,
HS-410 is open for enrolment. Heat Biologics is developing the
candidate for the treatment of patients suffering from bladder
The company is expected to enrol 93 patients for the phase I/II
study. The study will evaluate whether vaccination with HS-410,
post transurethral resection of bladder tumor (TURBT) and
bacillus Calmette-Guérin (BCG), delays disease recurrence
compared to placebo.
Heat Biologics will further evaluate the safety profile of the
candidate in patients suffering from bladder cancer. The first
patient in the phase I/II study is expected to be dosed later
As per data from the American Cancer Society, 73,000 new bladder
cancer cases along with 15,000 deaths were reported in the U.S.
in 2012. Heat Biologics also mentioned in its press release
that no drugs were approved in the U.S. for the treatment of
bladder cancer in more than 25 years.
Apart from HS-410, Heat Biologics' oncology pipeline also
includes HS-110. The company intends to initiate a phase II study
on HS-110 in patients suffering from non-small cell lung cancer.
We are encouraged by the company's progress with its oncology
pipeline so far. We note that the oncology market has big players
Heat Biologics currently carries a Zacks Rank #3 (Hold). Some
other stocks worth considering include
Forest Laboratories Inc.
). Both the stocks carry a Zacks Rank #1 (Strong Buy).